The company exhibits no operating leverage, as evidenced by persistent quarterly net losses, including a $2.7 million loss in 2026Q1, while maintaining zero revenue generation.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 6K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -6K | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | -10.54M | -11.63M | 12.57M | 4.68M | 3.86M | 943.93K | 195.86K |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.8M | 4.48M | 6.73M | 928K | 577K | 943.93K | 195.86K |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 7.92M | 7.14M | 5.82M | 3.71M | 3.23M | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | -997K | -23.25M | 25K | 45K | 57K | 0 | 0 |
| Operating Income | 10.53M | 11.63M | -12.57M | -4.68M | -3.86M | -943.93K | -195.86K |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 192.53% | -168.55% | -21.27% | -308.93% | -381.94% | - |
| EBITDA | 10.54M | 11.65M | -12.55M | -4.64M | -3.8M | -755K | -195.86K |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | 195.33% | 192.83% | -170.62% | -21.9% | -403.71% | -285.48% | - |
| D&A (Non-Cash Add-back) | 12K | 14K | 25K | 45K | 57K | 0 | 0 |
| EBIT | -12.92M | -11.9M | -16.5M | -4.68M | -3.86M | -755K | -195.86K |
| Net Interest Income | 177K | 129K | -51K | 144K | 29K | 6.37K | 0 |
| Interest Income | 183K | 142K | 1K | 153K | 114K | 6.37K | 0 |
| Interest Expense | 6K | 13K | 52K | 9K | 85K | 0 | 0 |
| Other Income/Expense | -23.44M | -23.54M | -3.94M | -395K | 396K | 188.72K | 0 |
| Pretax Income | -12.91M | -11.91M | -16.51M | -5.08M | -3.46M | -755.22K | -195.86K |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 3K | 3K | 10K | 32K | 24K | 0 | 0 |
| Effective Tax Rate % | -0.02% | -0.03% | -0.06% | -0.63% | -0.69% | 0% | 0% |
| Net Income | -12.91M | -11.91M | -16.44M | -4.94M | -3.21M | -755.22K | -195.86K |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | 14.44% | 27.56% | -232.72% | -53.72% | -325.7% | -285.59% | - |
| Net Income (Continuing) | -12.91M | -11.91M | -16.52M | -5.11M | -3.49M | -755.22K | -195.86K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 3.42M | 3.59M | 0 | 0 |
| EPS (Diluted) | -39.96 | -89.60 | -26.40 | -44.20 | 0.35 | -0.46 | -0.12 |
| EPS Growth % | 403.07% | -239.39% | 40.27% | -12764.76% | 176.2% | -284.87% | - |
| EPS (Basic) | - | -89.60 | -26.40 | -44.20 | 0.35 | -0.46 | -0.12 |
| Diluted Shares Outstanding | 323.04K | 132.95K | 623.85K | 111.73K | 1.67M | 1.65M | 1.65M |
| Basic Shares Outstanding | 323.04K | 132.95K | 623.85K | 111.73K | 1.67M | 1.65M | 1.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Limited cash runway
As indicated by recent financial disclosures, Silexion Therapeutics maintains a high-burn cost structure, with R&D expenditures reaching $3.4 million in 2025Q4, reflecting the intense capital requirements necessary to advance the LODER delivery platform through its current clinical development phase without any offsetting commercial revenue streams.
The company's cost structure is almost entirely comprised of R&D and SG&A, which fluctuate significantly based on the timing of clinical trial activities. This lack of expense predictability suggests that management is prioritizing pipeline advancement over operational efficiency, which is typical for pre-revenue biotech firms but leaves little room for error.
Based on reported income statements, the company's net income figures are frequently impacted by non-operating items, such as the $18.9 million operating income spike in 2025Q4, which obscures the underlying reality of a business that continues to generate consistent quarterly net losses from core operations.
Investors should exercise caution when interpreting bottom-line results, as these non-recurring gains do not represent sustainable profitability or operational success. The volatility in EPS, ranging from -14.10 to 43.20, highlights the lack of earnings quality inherent in a company that relies on accounting adjustments rather than commercial product sales.
According to historical income statement data, Silexion Therapeutics exhibits no operating leverage, as the company has yet to generate revenue to scale against its fixed laboratory and personnel overhead, resulting in persistent negative operating margins that track directly with the intensity of its clinical trial spending.
The absence of revenue means that every dollar spent on R&D directly increases the operating loss, creating a linear relationship between clinical progress and cash depletion. Without a commercial product to provide scale, the company remains entirely dependent on external financing to cover its growing operational footprint.
As reported in recent filings, the company's cash position of $5.99 million appears insufficient to support long-term clinical development, suggesting that the firm faces a high probability of dilutive equity financing in the near term to sustain its current rate of operational cash burn.
Short-term observers may focus on the potential of the LODER platform, but the financial reality is that the company is rapidly approaching a liquidity wall. Unless management secures a strategic partnership or non-dilutive funding, the current trajectory implies that shareholders will likely face significant dilution to keep the pipeline active.
Quick answers to the most common questions about buying SLXNW stock.
For fiscal year 2025, Silexion Therapeutics Ltd. (SLXNW) reported total revenue of $0.0M.
Silexion Therapeutics Ltd. (SLXNW) reported a net loss of $11.9M for the fiscal year ending 2025.